Turpeenniemi-Hujanen T - Search Results

1

Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.

Peroja P, Pedersen M, Mantere T, Nørgaard P, Peltonen J, Haapasaari KM, Böhm J, Jantunen E, Turpeenniemi-Hujanen T, Rapakko K, Karihtala P, Soini Y, Vasala K, Kuittinen O. Peroja P, et al. Sci Rep. 2018 Oct 4;8(1):14814. doi: 10.1038/s41598-018-33230-3. Sci Rep. 2018. PMID: 30287880 Free PMC article.

2

p53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines.

Rämet M, Castrén K, Järvinen K, Pekkala K, Turpeenniemi-Hujanen T, Soini Y, Pääkkö P, Vähäkangas K. Rämet M, et al. Carcinogenesis. 1995 Sep;16(9):2117-24. doi: 10.1093/carcin/16.9.2117. Carcinogenesis. 1995. PMID: 7554063

3

Proliferating cell nuclear antigen but not p53 or human papillomavirus DNA correlates with advanced clinical stage in renal cell carcinoma.

Kamel D, Turpeenniemi-Hujanen T, Vähäkangas K, Pääkkö P, Soini Y. Kamel D, et al. Histopathology. 1994 Oct;25(4):339-47. doi: 10.1111/j.1365-2559.1994.tb01352.x. Histopathology. 1994. PMID: 7835839

4

p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression.

Soini Y, Turpeenniemi-Hujanen T, Kamel D, Autio-Harmainen H, Risteli J, Risteli L, Nuorva K, Pääkkö P, Vähäkangas K. Soini Y, et al. Br J Cancer. 1993 Nov;68(5):1029-35. doi: 10.1038/bjc.1993.475. Br J Cancer. 1993. PMID: 8217593 Free PMC article.

5

Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML.

Kuittinen O, Savolainen ER, Koistinen P, Turpeenniemi-Hujanen T. Kuittinen O, et al. Anticancer Res. 1999 Sep-Oct;19(5C):4395-400. Anticancer Res. 1999. PMID: 10650782

6

MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL).

Kuittinen O, Savolainen ER, Koistinen P, Möttönen M, Turpeenniemi-Hujanen T. Kuittinen O, et al. Leuk Res. 2001 Feb;25(2):125-31. doi: 10.1016/s0145-2126(00)00104-1. Leuk Res. 2001. PMID: 11166827

7

Amifostine does not protect malignant lymphoma cell lines from the cytotoxic effects of various chemotherapeutics in vitro.

Kuittinen O, Ruokolainen H, Turpeenniemi-Hujanen T. Kuittinen O, et al. Leuk Lymphoma. 2001 Jul;42(3):507-10. doi: 10.3109/10428190109064608. Leuk Lymphoma. 2001. PMID: 11699416

8

Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma.

Kuittinen O, Soini Y, Turpeenniemi-Hujanen T. Kuittinen O, et al. Eur J Haematol. 2002 Oct;69(4):205-12. doi: 10.1034/j.1600-0609.2002.02751.x. Eur J Haematol. 2002. PMID: 12431239

9

Gelatinases (MMP-2 and MMP-9), TIMP-1 expression and the extent of neovascularization in aggressive non-Hodgkin's lymphomas.

Kuittinen O, Apaja-Sarkkinen M, Turpeenniemi-Hujanen T. Kuittinen O, et al. Eur J Haematol. 2003 Aug;71(2):91-9. doi: 10.1034/j.1600-0609.2003.00101.x. Eur J Haematol. 2003. PMID: 12890147

10

Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer.

Vasala K, Pääkkö P, Turpeenniemi-Hujanen T. Vasala K, et al. Urology. 2003 Nov;62(5):952-7. doi: 10.1016/s0090-4295(03)00660-5. Urology. 2003. PMID: 14624933

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

161 results

Search Page

Filters